**Research Article**

**Development of Type 1 Diabetes Mellitus in Nonobese Diabetic Mice Follows Changes in Thymocyte and Peripheral T Lymphocyte Transcriptional Activity**

Thais A. Fornari, Paula B. Donate, Claudia Macedo, Elza T. Sakamoto-Hojo, Eduardo A. Donadi, and Geraldo A. Passos

1 Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14040-900, School Ribeirão Preto, SP, Brazil
2 Department of Biology, School of Philosophy, Science and Letters of Ribeirão Preto, USP, 14040-900 Ribeirão Preto, SP, Brazil
3 Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, USP, 14040-900, Ribeirão Preto, SP, Brazil
4 Disciplines of Genetics and Molecular Biology, Department of Morphology (DMEF), School of Dentistry of Ribeirão Preto, USP, 14040-900 Ribeirão Preto, SP, Brazil

Correspondence should be addressed to Geraldo A. Passos, passos@rge.fmrp.usp.br

Received 13 January 2011; Revised 21 March 2011; Accepted 22 March 2011

**1. Introduction**

Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of pancreatic insulin-producing beta cells [1, 2]. This destruction is a progressive process that occurs over five to eight months in the nonobese diabetic (NOD) mouse or several years in human patients [3]. The early stages of T1D pathogenesis are characterized by insulitis, an inflammation of the beta cells of the pancreas caused by lymphocyte infiltration. Nevertheless, the molecular genetics regulating the progress of beta cell failure and factors determining time of presentation of clinical diabetes are still poorly understood.
The thymus exerts an important role in controlling autoreactive T-cells. An extremely diverse repertoire of T-cells is generated through the random rearrangement of T-cell receptor (TCR) gene segments. This random process generates autoreactive T-cells that are eventually eliminated through negative selection, which occurs in the medullar compartment of the thymic stroma in close association with the medullary thymic epithelial cells (mTECs). The negative selection plays an essential role in preventing pathogenic autoimmune reactions and/or autoimmune diseases.

The mTECs are essentially self-antigen-presenting cells. These cells express most of the parenchymal organs’ self-antigens, a phenomenon that has been termed promiscuous gene expression (PGE) [23, 24]. Thymocytes are in close interaction with mTECs, establishing the thymic cross-talk. In fact, the self-antigens are coded from peripheral tissue antigen (PTA) genes. The translated PTAs are trimmed into peptides that are presented to thymocytes by means of the MHC. Dendritic cells also participate in the negative selection process after they have acquired PTA peptides from mTECs [23, 25–31].

Thymocyte clones that recognize self-peptide antigens during the cross-talk phase trigger a death gene expression cascade and die by apoptosis. Accordingly, the escaping autoreactive thymocytes from negative selection may cause severe aggressive reactions in the peripheral tissues and/or organs, provoking aggressive autoimmunity/autoimmune diseases. Thus, an imbalance in the central tolerance may have important consequences in the pathogenesis of autoimmune diseases, including T1D.

The central tolerance imbalance may explain, at least in part, the results of early studies using anti-CD3 antibodies; the results indicated that T1D in the NOD mouse is a T-cell-mediated disease [32].

We considered the following factors in our experiment: (1) peripheral T-cells represent the primary effectors in T1D autoreactivity in NOD mice; (2) the role played by autoreactive T-cells in the periphery may be a consequence of failure of the negative selection in the thymus; (3) the autoreactive phenotype of these cells may be a direct consequence of their transcriptional activity. Thus, our interest in this study was to analyze the transcriptome profile of thymocytes and peripheral CD3⁺ lymphocytes in the course of T1D in NOD mice to elucidate the sequential participation of genes associated with autoreactivity.

2. Materials and Methods

2.1. Animals, Thymocytes and Peripheral T CD3⁺ Lymphocyte Isolation. Female NOD mice were born in specific pathogen-free (SPF) conditions at the CEMIB-UNICAMP animal facility of the University of Campinas, SP, Brazil and maintained
in SPF mini-isolators in our laboratory at the University of São Paulo, Campus of Ribeirão Preto, SP, Brazil during the experiment. We studied prediabetic 1-month-old and diabetic 7-month-old animals. Diabetes was confirmed by blood glucose levels (≥250 mg glucose/dL) using the Accu-Chek Active kit (Roche Diagnostics Brazil, São Paulo, Brazil).

The thymi from 1-month-old animals were dissected and trimmed of fat and connective tissue in DMEM/F10 medium, and thymocytes were obtained by 2-3 passages of the thymic fragments throughout a 10-μm mesh nylon membrane (Sefar Inc. Depew, NY, USA). Pelleted thymocytes were resuspended in phosphate-buffered saline (PBS). Fluorescent-activated cell sorting (FACS) analysis in a BD-FACScalibur flow cytometer with phycoerythrin-(PE-) labeled anti-CD3 antibody indicated that this procedure yielded approximately 93% purity of the thymocyte population (Figure 1(a)). These cells were then used for total RNA preparation.

The peripheral T CD3+ lymphocytes from 1-month-old prediabetic, 7-month-old prediabetic, or 7-month-old diabetic animals were isolated from spleens using magnetic beads for negative selection (Pan T-cell isolation kit, mouse, Miltenyi Biotec) according to the manufacturer’s instructions. FACS analysis with PE-labeled anti-CD3 antibody indicated that this procedure yielded approximately 87% purity of the CD3+ T lymphocyte population (Figure 1(b)). These cells were then used for total RNA preparation. The animal experimental protocol was previously approved by the Commission for Ethics in Animal Research, Faculty of Medicine of Ribeirão Preto, USP, Brazil (Protocol no. 120/2008).
| Cluster | Biological process | Genes |
|---------|-------------------|-------|
| **Activation of immune system** | | Cd55 Daf2 Fcer1g Klre1 Klrk1 Lax1 Lyn Malt1 Maspl2 Plcg2 Trl3 Trl4 Trl6 Unc93b1 |
| **Adaptive immune response** | | Bcl3 Cd55 Cd74 Daf2 Fcer1g Fcg3 Icam1 Icosl Lirrb3 Maspl2 Pou2f2 Slc11a1 Trl6 |
| **Cell activation** | | Bank1 Bcl11a Bcl3 Btk Casp1 Cd74 Clcf1 Cplx2 Cxcr5 Elf4 Entpd1 Fcer1g Fcg3 Fyb Gapt Gpr183 H2-M3 Hdac9 Hhex Icosl Il4 Irf3 Irf4 Itgax Klre1 Klrk1 Lax1 Lbp Lirrb3 Lyn Malt1 Plcg2 Pou2f2 Slc11a1 Trl3 Trl4 Trl6 Vwf |
| **Defense response** | | Alox5 Bcl3 Btk Ccl19 Ccl5 Ccr2 Ccr5 Cd163 Cd180 Cd36 Cd55 Cd74 Chst2 Ciita Cleca4a Cleca4d Cpx2 Dafl Ddx58 Enpp1 Fasl Fcer1g Fcg3 Fcgrt Gpr183 H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8 H2-T23 Hfe Icam1 Icosl Il18rap Il1b Il4 Irf3 Irf8 Irf8 Lax1 Lbp Lirrb3 Lta Ltb Ly86 Lyn Malt1 Maspl2 Mefv Ncf1 Neurod2 Pglyr1 Prg2 Samhd1 Slc11a1 Tirap Trl3 Trl4 Trl6 |
| **I-kappa8 kinase/NF-kappa8 cascade** | | Btk Ira2 Malt1 Rel Tirap Trl4 |
| **Immune effector process** | | Bcl3 Btk Cd55 Cd74 Cplx2 Dafl Fcer1g Fcg3 Icam1 Icosl Lax1 Lbp Lirrb3 Lyn Maspl2 Ncf1 Pou2f2 Slc11a1 |
| **Immune system process** | | Bcl3 Btk Ccl19 Ccl5 Ccl9 Ccr2 Cd180 Cd55 Cd74 Ciita Cleca4a Cleca4d Cplx2 Dafl Ddx58 Enpp1 Fasl Fcer1g Fcg3 Fcgrt Gpr183 H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8 H2-T23 Hfe Icam1 Icosl Il18rap Il1b Il4 Irf3 Irf4 Irf8 Itgax Klre1 Klrk1 Lax1 Lbp Lirrb3 Lta Ltb Ly86 Lyn Malt1 Maspl2 Mefv Ncf1 Oas1b Pglyr1 Plcg2 Pou2f2 Prg2 Samhd1 Slc11a1 Tirap Trl3 Trl4 Trl6 Unc93b1 |
| **Immune response-activating signal transduction** | | Fcer1g Klre1 Klrk1 Lax1 Lyn Malt1 Plcg2 Trl3 Trl4 Trl6 Unc93b1 |
| **Inflammatory response** | | Bank1 Bcl11a Bcl3 Btk Casp1 Ccl19 Ccl5 Ccf1 Ccr2 Cd180 Cd300lf Cd55 Cd74 Ciita Cleca4a Cleca4d Cplx2 Dafl Ddx58 Dnase2a Elf4 Enpp1 Fasl Fcer1g Fcg3 Fcgrt Gpr183 H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8 H2-T23 Hfe Icam1 Icosl Il18rap Il1b Il4 Irf3 Irf8 Irf8 Lax1 Lbp Lirrb3 Lta Ltb Ly86 Lyn Malt1 Maspl2 Mefv Ncf1 Oas1b Pglyr1 Plcg2 Pou2f2 Prg2 Samhd1 Slc11a1 Tirap Trl3 Trl4 Trl6 Tnfrsf13c Unc93b1 |
| **Lymphocyte activation** | | Alox5 Bcl3 Btk Ccl19 Ccl5 Ccr2 Cd163 Cd180 Cd55 Chst2 Cnr2 Dafl |
| **Lymphocyte activation during immune response** | | Bank1 Bcl11a Bcl3 Ccl19 Ccl5 Ccl9 Ccr2 Cd180 Cd300lf Cd55 Cd74 Ciita Cleca4a Cleca4d Cplx2 Dafl Ddx58 Dnase2a Elf4 Enpp1 Fas Fcer1g Fcg3 Fcgrt Gpr183 H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8 H2-T23 Hfe Icam1 Icosl Il18rap Il1b Il4 Irf3 Irf8 Irf8 Itgax Klre1 Klrk1 Lax1 Lbp Lirrb3 Lta Ltb Ly86 Lyn Malt1 Maspl2 Mefv Ncf1 Oas1b Pglyr1 Plcg2 Pou2f2 Prg2 Samhd1 Slc11a1 Tirap Trl3 Trl4 Trl6 Tnfrsf13c Unc93b1 |
| **Lymphocyte mediated immunity** | | Bcl3 Cg55 Cd74 Dafl Fcer1g Fcg3 Icam1 Icosl Lirrb3 Maspl2 Pou2f2 Slc11a1 |
| **Positive regulation of interferon-gamma production** | | Bcl3 H2-M3 Irf8 Klre1 Klrk1 Lta Slc11a1 Trl4 |
| **Regulation of defense response** | | Adrb2 Anxa1 Cadm1 Cdt5 Ccr5 Cnr2 Crtam Fcer1g Fcg3 H2-Bl H2-M3 Klr1b1b Klre1 Klrk1 Lta Tn5e Tgm2 Trl4 Trl6 Unc93b1 |
| **Regulation of immune effector process** | | Cadm1 Crtam Fcer1g Fcg3 H2-Bl H2-K1 H2-M3 Hmox1 Klr1b1b Klre1 Klrk1 Lta |
| **Regulation of immune response** | | Btla Cadm1 Cg55 Crtam Dafl Fcer1g Fcg3 H2-Bl H2-K1 H2-M3 Il4 Klr1b1b Klre1 Klrk1 Lax1 Lta Lyn Malt1 Maspl2 Plcg2 Slc11a1 Trl3 Trl4 Trl6 Tnfrsf13c Unc93b1 |
| **Regulation of inflammatory response** | | Adrb2 Anxa1 Cdt5 Cnr2 Fcer1g Fcg3 Lta Tn5e Tgm2 Trl4 |
| **Regulation of leucocyte mediated cytotoxicity** | | Cadm1 Crtam H2-Bl H2-K1 H2-M3 Klr1b1b Klre1 Klrk1 |
| **Apoptosis** | | Act1 Bag3 Dap1 Dedd2 Fasl Gramd4 Hkap2 Nknb1 Nod1 Pea15a Pim2 Pmaip1 Psen2 Ripk1 Sbk1 Sgms1 Shisa5 Tmem173 Traf1 Traf3ip2 Traf5 |
| Cluster | Biological process                              | Genes                                                                 |
|---------|------------------------------------------------|----------------------------------------------------------------------|
| Immune response | | B2m Cc13 Cc5 Cxcl9 Eomes Fasl Foxp3 H2-Q10 Il1r1 Il1r1 Il1r Tnfalpha Traf1 Trafip2 |
| 2       | Immune system process                          | B2m Cc13 Cc5 Cxcl9 Eomes Fasl Flt3 Foxp3 Gimap5 H2-Q10 Il1r1 Il1r2 Il7r Ilrf1 Irgm1 Jak3 Mpd8 Fasl P2x7 Pd3 Pk3d Psen2 Psmf1 Tgfbr2 Tgtp1 Tlr1 Tmem173 Tnafip8 Traf3 Trafip2 |
| Regulation of I-kappaB kinase/NF-kappaB cascade | | Card6 Il1r1 Nod1 Pim2 Tgm2 |
| Regulation of signal transduction | | Arggef12 Arhgef3 Arrbl Arrb2 Axin2 Card6 Cd44 Fasl Furin Il1r1 Nod1 P2x7 Pim2 Psen2 Rasa3 Rasgrp2 Rgs11 Rums2 S1pr1 Smad7 Soc3 Stry2 Tgm2 Zeb2 |
| 3       | Immune system process                          | Add2 Ahspl Ank1 Ccl4 Ccr2 Cda4 Cebpa Csf1 Epsp1 Epb4.2 Gimap5 Gm5077 Ld2 Ifng Il1r1 Il1r1 Il1r2 Ilgam Junb Kif11 Mpo Psrc1 Polr3c Samhd1 Sna1 Tali Tgtp1 Trim10 Txnrd2 Zbtb32 |
| 4       | Cell communication                             | Atg161 Bmp8a Cacna1c Cblc Chat Cldn5 Cxcr7 Drd5 Erbb3 Gad1 Gad2 Gata4 Gnat Gpla Gpr12 Gpr173 Gpr82 Grp Grpr Hn1b Itgax Kcnk2 Lin7a Mrgprb2 Negr Olfr1010 Olfr1022 Olfr1048 Olfr107 Olfr1090 Olfr1115 Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388 Olfr1459 Olfr1462 Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350 Olfr365 Olfr516 Olfr523 Olfr556 Olfr606 Olfr65 Olfr68 Olfr684 Olfr724 Olfr768 Olfr770 Olfr774 Olfr790 Olfr796 Olfr845 Olfr889 Olfr904 Olfr924 Olfr974 Park2 Pdx1 Pik3c2b Plat Pth Rah3b Rah3c Slc1a2 Slc6a4 Syn2 Taar4 Tac1 Upk1a Vmn226 Vmn2r81 Xcr1 |
| G-protein coupled receptor protein signaling pathway | | Cxcr7 Drd5 Gata Gnat Gpr12 Gpr173 Gpr82 Grp Grpr Kcnk2 Mrgprb2 Olfr1010 Olfr1022 Olfr1048 Olfr107 Olfr1090 Olfr1115 Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388 Olfr1459 Olfr1462 Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350 Olfr516 Olfr523 Olfr556 Olfr606 Olfr651 Olfr684 Olfr724 Olfr768 Olfr770 Olfr774 Olfr790 Olfr796 Olfr845 Olfr889 Olfr904 Olfr924 Olfr974 Pth Taar4 Tac1 Vmn2r26 Vmn2r81 Xcr1 |
| Signal transduction | | Bmp8a Cblc Cxcr7 Drd5 Erbb3 Gata Gnat Gp12 Gpr173 Gpr82 Grp Grpr Itgax Kcnk2 Mrgprb2 Negr Olfr1010 Olfr1022 Olfr1048 Olfr107 Olfr1090 Olfr1115 Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388 Olfr1459 Olfr1462 Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350 Olfr516 Olfr523 Olfr556 Olfr606 Olfr651 Olfr684 Olfr724 Olfr768 Olfr770 Olfr774 Olfr790 Olfr796 Olfr845 Olfr889 Olfr904 Olfr924 Olfr974 Pth Taar4 Tac1 Vmn2r26 Vmn2r81 Xcr1 |
| Apoptosis, apoptosis regulation | | Alms1 Bcl2l1 Birc5 Bub1 Bub1b Casp6 Ckap2 Cull E2f1 E2f2 Egln3 Epha2 Fasl Fgfr5 Krt18 Krt8 Lig4 Phlda1 Rad21 Rtn3 Stk3 Tfdp1 Tia1 Tpx2 Traf4 Trp3 Imp1 Vdac1 |
| Cell activation | | Ada Bcl11b Ccnd3 Cd4 Cd8a Cxcl12 Dax Hdac7 Hells Lig4 Ly6d Msh6 Patz1 Rag1 Rorc Satb1 Sox4 Temhis |

| 5       | Cell cycle                                     | 1190002H23Rik Anapc5 Anapl Asnpd Aurka B230120H23Rik Birc5 Bub1 Bub1b C79407 Caspc5 Cdc99 Cenab Cenbl Cenb2 Cencl Ccn2 Ccnf Ceng2 Cdc20 Cdc25a Cdc25c Cdc45 Cdc2a Cdc3a Cdc5a Cdk1 Cdkn1a Cdkn2c Cdkn3 Cenpe Cenpi Cep5 Chek1 Ckap2 Ckap5 Cul7 E2f1 E2f2 E2f3 E2f7 Ercc16 Cses2 Esp1 Fh30043a40Rik Fam33a Fbxos Gas23 Gag2 H2afx Haus2 Hells Kif11 Ki67 Kif1c Lig4 Mad111 Mki67 Mbp Ncapd2 Ncapf Ndc80 Nde1 Nek2 Nsl1 Nuf2 Nusap1 Pard6 Phgdh Prc1 Prc1 Pttg1 Rad21 Rad53c Rbpb4 Rec1 Sgo1 Sgo2 Skp2 Spag5 Spc25 Stmnt1 Tac2 Tac3 Tfdp1 Tpx2 Trp3 Imp1 Tub65 Tubg1 Ube2c Uhrf1 Weel |
2.2. Total RNA Preparation. The total RNA was extracted from $1 \times 10^7$ thymocytes or peripheral T CD3+ lymphocytes using a mirVana total RNA isolation kit (Ambion) according to the manufacturer’s instructions. RNA preparations were confirmed to be free of proteins and phenol by UV spectrophotometry. The state of degradation was assessed by microfluidic electrophoresis using Agilent RNA Nano 6000 chips and an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only RNA samples that were free of proteins and phenol and featured an RNA Integrity Number (RIN) $\geq 9.0$ were used.

2.3. RNA Amplification, Labeling, Microarray Hybridization and, Data Analysis. Changes in gene expression were evaluated using the Agilent one-color (Cy3 fluorochrome) microarray-based gene expression platform according to the manufacturer's instructions. For hybridization onto whole mouse genome 4 x 44 K 60-mer oligonucleotide arrays (G4122F, Agilent Technologies, Santa Clara, CA, USA), 500 ng total RNA was used in the one-color Quick Amp labeling kit (Agilent Technologies, Santa Clara, CA, USA). Samples of complementary RNA (cRNA) were hybridized for 18 h at 42°C in a rotator oven and were then washed. The array slides were scanned using a DNA microarray scanner (Agilent Technologies), and the hybridization signals were extracted using the Agilent Feature Extraction software version 10.5.

Gene expression profiles from independent preparations of thymocytes (from 1-month-old prediabetic mice) or CD3+ peripheral lymphocytes (from 1-month-old prediabetic, 7-month-old prediabetic or 7-month-old diabetic mice) were analyzed through comparisons of the microarray hybridizations of the respective samples. Figure 2 depicts the experimental design for further comparison of the gene profiling.

A complete file that provides all of the genes present in the microarray used in this study, as well as the experimental conditions, is available online at the MIAME public database [33], ArrayExpress accession E-MEXP 3047.

The microarray numerical quantitative data were normalized to the 75th percentile and were analyzed using the GeneSpring GX bioinformatics platform [34] according to the default instructions allowing hierarchical clustering of samples of mice or genes based on ANOVA statistical analysis ($P < .01$) with a fold change $>2.0$ and an uncentered Pearson correlation metrics [35]. The similarities and dissimilarities in gene expression are presented as dendrograms, in which the pattern and length of the branches reflect the relatedness of the samples or genes, and heat maps.

2.4. Gene Ontology. Microarray data analysis was used to identify gene expression based on combined information from the public databases DAVID [36] and SOURCE [37]. These databases show gene annotation enrichment analysis, functional annotation clustering, BioCarta and KEGG pathway mapping (DAVID), or microarray data and sequencing...
of cDNA clones from different organ/tissues (SOURCE), including GenBank accession number, chromosomal location and the molecular/biological function of each gene analyzed.

2.5. Oligonucleotide Primer Design and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Microarray data were confirmed using qRT-PCR for the genes listed below that were differentially expressed between thymocytes and peripheral CD3+ T lymphocytes. The cDNA sequences of these genes were retrieved from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/genbank/GenbankSearch.html), and the Primer3 web tool (http://biotools.umassmed.edu/bioapps/primer3www.cgi) was used to select pairs of oligonucleotide primers spanning an intron/exon junction and with consideration of the alternative transcripts. An optimal melting temperature of 60°C was standardized for all genes. The following forward and reverse sequences are given in the 5'C to 3' orientation: Hypoxanthine phosphoribosyltransferase 1 (HPRT1, accession number NM_000194.2, GACCAGTCAA CAGGGGACACT and CTGCA TTGTTTTGCCAGTGT); Fas ligand (Fasl, accession number NM_000639, ACTCCGTG AGTTCAACAC and GTGGGGGTTCCTCTTAAAT); Toll-like receptor 3 (Tlr3, accession number BC068487, TGTGTCTCTGCACAAGTGGC and CCCGTTACCAACTT TGTAGA); Toll-like receptor 4 (Tlr4, accession number NM_138554, TCAGAACTTCAGTGGCAGGA CCTGGGGA AAAACTCTGGAT); Forkhead box P3 (Foxp3, accession number NM_014009, TCTTCGAGGAGCCAGAAGAG and GCTCCAGAGACTGCACC); Thymocyte selection associated (Themis, accession number NM_001164685, AATG AAGCTTACCTTGCTCA and ATCCGTGGCCAATTTCACT TG). HPRT1 was used as the constitutively expressed gene. Transcriptional expression levels were determined using a StepOne Real-Time PCR System (Applied Biosystems, USA). The ΔΔCT relative normalization method was used as described previously. We used the GraphPad Prism 5.00 tool (http://www.graphpad.com/prism/Prism.html) to run one-way or two-way ANOVAs with Bonferroni's correction statistics.

3. Results

Although the expression pattern remained unchanged between thymocytes and peripheral T lymphocytes from prediabetic and diabetic animals for the majority of the 44,000 sequences tested, which presented a control/test ratio ≈ 1.0 (Pearson correlation), 2,771 genes were found to be differentially expressed. Hierarchical clustering of the data allowed for the identification of clusters of upregulated (induced) and downregulated (repressed) genes. Changes in gene expression profile could be observed when comparing thymocytes from 1-month-old prediabetic mice with peripheral CD3+ lymphocytes from 1-month-old prediabetic, 7-month-old prediabetic, or 7-month-old diabetic mice to observe the modulated genes that coincided with the development of T1D.
Figure 4: Confirmation of microarray data by qRT-PCR. The Fasl, Tlr3, and Tlr4 genes were downregulated in thymocytes from prediabetic animals, Foxp3 was upregulated in peripheral CD3⁺ lymphocytes from diabetic animals, and Themis was upregulated in thymocytes from prediabetic animals.
Hierarchical clustering analysis depicted in Figure 3 shows variability in the hybridization signatures between cell types. The upper horizontal dendrogram (cell samples) demonstrates that this variability could distinguish cells according to their developmental phase, namely, thymocytes (prediabetic animals) from peripheral CD3+ lymphocytes (prediabetic and diabetic animals). The left vertical dendrogram shows the genes that were differentially expressed (up- or downregulated) according to their respective biological function, and the genes were divided into six clusters (Figure 3 and Table 1). Clusters 1 to 4 contain genes downregulated in thymocytes and peripheral CD3+ lymphocytes from 1-month-old prediabetic animals and progressively upregulated in peripheral CD3+ lymphocytes from 7-month-old prediabetic and diabetic animals.

Cluster 1 comprises 767 differentially expressed genes, and the following genes were highlighted because they participate in immune processes potentially implicated in the pathogenesis of T1D: IL4, involved with T-cell activation, Crtam, involved in cytotoxicity and Tlr3, Tlr4, and Tlr6, involved in inflammatory response.

Cluster 2 comprises 340 differentially expressed genes, and the following genes were highlighted: Fasl, involved in the induction of apoptosis by extracellular signals and Foxp3, involved in CD25+ alpha-beta T-regulatory (Treg) cell differentiation and positive regulation of T-cell tolerance induction.

Cluster 3 comprises 435 differentially expressed genes, and the following genes were highlighted: Chemokine (C–C motif) ligand 4 gene (Ccl4) and Chemokine (C–C motif) receptor 2 gene (Ccr2), both involved in inflammatory response; CD48 antigen gene, involved in T-cell activation; Cytotoxic T-lymphocyte-associated protein 4 gene (Ctla4), involved in negative regulation of Treg cell differentiation; Interferon gamma gene (Ifng), involved in positive regulation of T-cell proliferation; Integrin alpha M gene (Itgam), involved in cell-cell adhesion.

Cluster 4 comprises 292 differentially expressed genes, and the following genes were highlighted: Integrin alpha X (Itgax) and Claudin 5 (Cldn5) gene, involved in cell-cell adhesion; Gap junction protein, alpha 5 (Gja5) gene, involved in cell-cell signaling; HNF1 homeobox 1 transcription factor, involved in maturity onset diabetes of the young and circadian regulation of transcription; and Gastrin (Gast) and Guanine nucleotide-binding protein 1 (Gna1) gene, both involved in protein signaling pathway. Interestingly, this cluster comprises various members of the olfactory receptor (Olfr) gene family, which is involved with cell signaling pathways.

Finally, clusters 5 and 6 comprise 610 and 327 genes, respectively, which feature a different expression pattern than those included in the previous clusters, that is, they were mainly upregulated in thymocytes from prediabetic mice and progressively downregulated in peripheral CD3+ lymphocytes from prediabetic and diabetic animals. These two clusters contain genes involved in CD4/CD8 cell differentiation (Themis) and V(D)J recombination (Rag1 and Rag2).

Using qRT-PCR, we assayed the expression levels of five differentially expressed genes (Fasl, Tlr3, Tlr4, Foxp3 and Themis) that are associated with thymocyte selection, T-cell differentiation, cell activation, or inflammation. The expression levels obtained with qRT-PCR method were comparable with microarrays, for example; the Fasl, Tlr3 and Tlr4 genes were downregulated in thymocytes from prediabetic animals, Foxp3 was upregulated in peripheral CD3+ lymphocytes from diabetic animals, and Themis was upregulated in thymocytes from prediabetic animals (Figure 4).

4. Discussion

In this study, we assessed the hypothesis that the transcriptional modulation of immune reactivity genes may occur during the development of T1D as thymocytes mature into peripheral T lymphocytes. Consequently, the emergence of T1D might follow a pattern of the transcriptional activity of these cells, sequentially featuring genes associated with a negative selection of thymocytes, T-cell maturation, differentiation, and autoreactivity.

As discussed in a previous study [38], diabetes in NOD mice is similar to T1D patients, and the progress of diabetes in these animals occurs in two stages. In the first stage, autoreactive CD8+ T lymphocytes infiltrate the pancreatic islet by 1 month after the birth. However, most pancreatic islets are preserved at this phase, and the animals are clinically healthy. Stage one can persist for months because the autoimmune attack is under control and is relatively nondestructive. In the second stage, most of pancreatic islets are destroyed and animals are often diabetic.

Because these animals spontaneously develop autoimmune diabetes mellitus that is similar to human T1D, including the presence of pancreas-specific autoantibodies and autoreactive CD4+ or CD8+ T-cells and syntenic to human chromosomal linkage groups associated with T1D, they are a classical model system for investigating autoimmune T1D and/or failure in the tolerance mechanisms [4, 6, 28]. Thus, we chose to employ the NOD mouse as a model system given the difficulty of easily testing this theory in humans.

To exclude the influence of genetic backgrounds of nonautoimmune mouse strains, we compared only groups of NOD mice in two distinct phases of autoimmunity, namely, prediabetic (1- or 7-month-old) and diabetic (≥7-month-old).

Moreover, by establishing transcriptome comparisons between cells from prediabetic and diabetic animals or between thymocytes and peripheral T lymphocytes, it was possible to find genes temporally regulated (because T1D emerges according to age) and regulated according to T-cell development.

The procedures for isolation of thymocytes and peripheral CD3+ T lymphocytes used in this work yielded purities (approximately 93% for thymocytes and 85% for peripheral CD3+ T lymphocytes) that are comparable to automated cell sorting of T-cells. Moreover, the peripheral CD3+ T lymphocytes were isolated by negative separation, minimizing eventual cell activation by artifacts.
Figure 3 (clusters 1 to 4) and Table 1 show the gene expression pattern observed in thymocytes and peripheral CD3+ lymphocytes from prediabetic 1-month-old animals. The gene expression in these cells could be considered to occur in the first stage of T1D, and this expression features the down-regulation of genes involved with the activation of the immune system/adaptive response, cell activation, NF-KappaB cascade, immune effector/immune response processes, inflammatory response, lymphocyte activation, the regulation of interferon-gamma production, the regulation of leukocyte-mediated cytotoxicity, apoptosis, cell communication, and signal transduction. Altogether, these biological processes are necessary for the development of lymphocyte differentiation and autoreactivity.

The thymocytes from prediabetic 1-month-old animals featured down-regulation of genes associated with several biological processes that were gradually upregulated in the peripheral CD3+ lymphocytes from prediabetic 1-month-old, prediabetic 7-month-old, and diabetic 7-month-old animals (Figure 3 and Table 1). Among these processes and their respective genes, we selected some of the most important to discuss because of their direct or indirect association with autoimmune diabetes.

The apoptosis process featured genes including Fas ligand (Fasl), TNF receptor-associated factor (Trf1 and Trf5), Trf3 interacting protein 2 (Trf3ip2), and Tumor necrosis factor (ligand) superfamily, member 8 (Tnfsf8 or TRAIL).

Because apoptosis is the final stage of the negative selection of thymocytes in the thymus [29], the down-regulation of these genes may favor the survival of autoreactive thymocyte clones, including those that recognize pancreatic beta cell autoantigens.

A role for TRAIL in T1D in NOD mice has been evidenced by its blockade with consequent exacerbation of the disease [39] and by its systemic delivery indicating that T1D can be prevented by TRAIL overexpression through an enhancement of the tissue inhibitor of the metalloproteinase-1 (TIMP-1) function [40]. The authors concluded that elevated TIMP-1 production inhibits the activity of matrix metalloproteinases, which may contribute to the suppression of the transmigration of diabeticogenic T-cells into the pancreatic islets and protects pancreatic beta cells from cytokine-induced apoptosis.

The tolerance induction process featured Forkhead box P3 (Foxp3) gene, which was also downregulated in thymocytes from 1-month-old prediabetic animals. This gene is involved in tolerance induction via CD4+/CD25+ T-regulatory cells (Tregs) [41–43], a process that directly activates any of the steps required for tolerance, a physiologic state in which the immune system does not react destructively against self-components. Thus, their deregulation may impair the Treg-mediated suppression of aggressive autoimmune activity, favoring the survival of autoreactive thymocytes in the thymus.

The T-cell activation process featured several downregulated genes in thymocytes from 1-month-old prediabetic animals, from which we highlight Chemokine (C–C ligand motif) ligand 4 (Ccl4), Chemokine (C–C motif) receptor 2 (Ccr2), Cd48 antigen and Interferon, gamma (Iifng), and Interleukin 4 (IL4) genes. These genes were gradually upregulated in peripheral CD3+ lymphocytes from prediabetic to diabetic animals and may increase the activation of autoreactive T-cell clones in the periphery.

Interestingly, the G-protein-coupled receptor protein signaling pathway and signal transduction processes shared several members of the olfactory gene family (Olfr), which is involved in sensory perception of smell through receptor and signal transducer activity. The two pathways also shared bone morphogenetic protein 8a (Bmp8a) gene, which is involved in growth and ossification. These genes were downregulated in thymocytes from 1-month-old prediabetic animals and were gradually upregulated in peripheral CD3+ lymphocytes from prediabetic to diabetic animals. Despite their disparate biological processes in the context of T1D, these genes may play a role in the receptor-mediated signal transduction activity of peripheral T-cells in diabetic animals.

Dissimilar from the pattern of genes related to the processes discussed above, the T-cell receptor V(D)J recombination and CD4+/CD8+ T-cell differentiation featured genes were upregulated in thymocytes and CD3+ peripheral T lymphocytes from prediabetic 1-month-old animals and were gradually downregulated in peripheral CD3+ lymphocytes from prediabetic and diabetic 7-month-old animals.

Among these genes, we highlight the recombination activating genes (Rag-1 and Rag-2) that code the recombinase catalytic complex involved in the recognition of recombination signal sequences (RSS) within the T-cell receptor loci (TCR alpha, beta, gamma or delta), cutting and recombining DNA during aleatory generation of TCR diversity. The generation of TCR diversity implies the production of T-cell clones directed to foreign antigens and also autoreactive clones. Autoreactive clones are normally eliminated by apoptosis throughout the negative selection process.

Also, Adenosine deaminase (Ada) gene, which is involved in a process that increases the frequency of T-cell differentiation in the thymus, and Cytotoxic T-lymphocyte-associated protein 4 (Ctla4) gene, which in contrast to Ada gene, is involved in the negative regulation of T-cell proliferation, were both identified.

Finally, we found the Thymocyte selection associated (Themis) gene, which is expressed in the thymus and to a lesser extent in the spleen but is not detectable in nonlymphoid tissues. This gene is highly expressed in thymocytes between the pre-T-cell antigen receptor (pre-TCR) and positive-selection checkpoints and is expressed at a low level in mature T-cells (at the protein level). Themis is also implicated in the control of T-helper CD4+/cytotoxic CD8+ cell fate. Moreover, the CD4 as well as CD8a antigen genes, which define the respective T-helper CD4+ or T cytotoxic CD8+ phenotypes, were also found.

During their permanence within the thymus, thymocytes activate a developmentally complex mechanism because of close contact with thymic stroma. The medullary thymic epithelial cells (mTECs), which form the stromal medullar compartment, present peripheral tissue antigens (PTAs) to thymocytes to eliminate autoreactive clones by inducing...
apoptosis (negative selection), leading to tolerance induction [23, 24]. Failure in the expression of specific PTA genes in the thymic stroma is strongly associated with aggressive autoimmunity as recently observed during the development of T1D in NOD mice [38] or collagen-induced arthritis in DBA-1/J mice [44]. This indeed led to survival of autoreactive thymocyte clones that once in the periphery, mediate autoimmune attack of target structures such as pancreatic beta cells.

To better understand the control of transcriptional activity of thymocytes specifically associated with the induction of tolerance and negative selection within the thymus or cytotoxicity and inflammatory response in peripheral T lymphocytes, we propose further experiments to evaluate the participation of microRNAs (miRNAs) that once dysregulated might be associated with aggressive autoimmunity of T1D.

5. Conclusion

In this study, we were able to construct a transcriptional profile of T-cell development comparing thymocytes with peripheral CD3+ lymphocytes in the context of the emergence of T1D. The sequential participation of genes involved with the main steps of T-cell development such as the generation of TCR diversity, CD4+/CD8+ cell fate, apoptosis, and negative selection demonstrated that the T1D autoimmune phenotype in NOD mice runs in parallel with transcriptome changes of T-cells. The results obtained confirm our initial hypothesis.

Acknowledgments

This study was funded by the following agencies: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). T. A. Fornari and Paula B. Donate are equally contributed to this work.

References

[1] A. L. Notkins and Å. Lernmark, “Autoimmune type 1 diabetes: resolved and unresolved issues,” Journal of Clinical Investigation, vol. 108, no. 9, pp. 1247–1252, 2001.
[2] B. Regnault, J. Osorio Y Fortea, D. Miao, G. Eisenbarth, and E. Melanitou, “Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity,” BMC Medical Genomics, vol. 2, article no. 63, 2009.
[3] E. H. Leiter, M. Prochazka, and D. L. Coleman, “The non-obese diabetic (NOD) mouse,” American Journal of Pathology, vol. 128, no. 2, pp. 380–383, 1987.
[4] M. A. Atkinson and E. H. Leiter, “The NOD mouse model of type 1 diabetes: as good as it gets?” Nature Medicine, vol. 5, no. 6, pp. 601–604, 1999.
[5] M. S. Anderson and J. A. Bluestone, “The NOD mouse: a model of immune dysregulation,” Annual Review of Immunology, vol. 23, pp. 447–485, 2005.
[6] J. P. Driver, D. V. Serrezee, and Y. -G. Chen, “Mouse models for the study of autoimmune type 1 diabetes: a NOβ to similarities and differences to human disease,” Seminars in Immunopathology, vol. 33, no. 1, pp. 67–87, 2011.
[7] H. Ikegami, S. Makino, E. Yamato et al., “Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping,” Journal of Clinical Investigation, vol. 96, no. 4, pp. 1936–1942, 1995.
[8] L. S. Wicker, J. A. Todd, and L. B. Peterson, “Genetic control of autoimmune diabetes in the NOD mouse,” Annual Review of Immunology, vol. 13, pp. 179–200, 1995.
[9] J. A. Shizuru, C. Taylor-Edwards, B. A. Banks, A. K. Gregory, and C. G. Fathman, “Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes,” Science, vol. 240, no. 4852, pp. 659–662, 1988.
[10] F. S. Wong, I. Visintin, Li. Wen, J. Granata, R. Flavell, and C. A. Janeway, “The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7-1) mice,” Journal of Experimental Medicine, vol. 187, no. 12, pp. 1985–1993, 1998.
[11] BO. Wang, A. Gonzalez, C. Benoist, and D. Mathis, “The role of CD8 T cells in the initiation of insulin-dependent diabetes mellitus,” European Journal of Immunology, vol. 26, no. 8, pp. 1762–1769, 1996.
[12] J. Katz, C. Benoist, and D. Mathis, “Major histocompatibility complex I molecules are required for the development of insulitis in non-obese diabetic mice,” European Journal of Immunology, vol. 23, no. 12, pp. 3358–3360, 1993.
[13] D. V. Serrezee, E. H. Leiter, G. J. Christianson, D. Greiner, and D. C. Roopenian, “Major histocompatibility complex class I-deficient NOD-B2m(null) mice are diabetes and insulitis resistant,” Diabetes, vol. 43, no. 3, pp. 505–509, 1994.
[14] T. Sumida, M. Furukawa, A. Sakamoto et al., “Prevention of insulitis and diabetes in β-microglobulin-deficient non-obese diabetic mice,” International Immunology, vol. 6, no. 9, pp. 1445–1449, 1994.
[15] J. D. Katz, B. Wang, K. Haskins, C. Benoist, and D. Mathis, “Following a diabetogenic T cell from genesis through pathogenesis,” Cell, vol. 74, no. 6, pp. 1089–1100, 1993.
[16] B. Bergman and K. Haskins, “Islet-specific T-cell clones from the NOD mouse respond to β-granule antigen,” Diabetes, vol. 43, no. 2, pp. 197–203, 1994.
[17] A. Gonzalez, J. D. Katz, M. G. Mattei, H. Kikutani, C. Benoist, and D. Mathis, “Genetic control of diabetes progression,” Immunity, vol. 7, no. 6, pp. 873–883, 1997.
[18] O. Kanagawa, A. Militech, and B. A. Vaupel, “Regulation of diabetes development by regulatory T cells in pancreatic islet antigen-specific TCR transgenic nonobese diabetic mice,” Journal of Immunology, vol. 168, no. 12, pp. 6159–6164, 2002.
[19] L. Poiriot, C. Benoist, and D. Mathis, “Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8102–8107, 2004.
[20] S. Zucchelli, P. Holler, T. Yamagata, M. Roy, C. Benoist, and D. Mathis, “Defective central tolerance induction in NOD mice: genomics and genetics,” Immunity, vol. 22, no. 3, pp. 385–396, 2005.
[21] K. L. Rock, S. Gamble, and L. Rothstein, “Presentation of exogenous antigen with class I major histocompatibility complex molecules,” Science, vol. 249, no. 4971, pp. 918–921, 1990.
[22] M. Kovacsovics-Bankowski and K. L. Rock, “Presentation of exogenous antigens by macrophages: analysis of major
histocompatibility complex class I and II presentation and regulation by cytokines," *European Journal of Immunology*, vol. 24, no. 10, pp. 2421–2428, 1994.

[23] B. Kyewski and J. Derbinski, “Self-representation in the thymus: an extended view,” *Nature Reviews Immunology*, vol. 4, no. 9, pp. 688–698, 2004.

[24] D. A. R. Magalhães, E. L. V. Silveira, C. M. Junta et al., “Promiscuous gene expression in the thymus: the root of central tolerance,” *Clinical and Developmental Immunology*, vol. 13, no. 2–4, pp. 81–99, 2006.

[25] L. Klein and B. Kyewski, “Self-antigen presentation by thymic stromal cells: a subtle division of labor,” *Current Opinion in Immunology*, vol. 12, no. 2, pp. 179–186, 2000.

[26] J. Derbinski, A. Schulte, B. Kyewski, and L. Klein, “Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self,” *Nature Immunology*, vol. 2, no. 11, pp. 1032–1039, 2001.

[27] B. Kyewski and L. Klein, “A central role for central tolerance,” *Annual Review of Immunology*, vol. 24, pp. 571–606, 2006.

[28] Y. Takahama, “Journey through the thymus: stromal guides for T-cell development and selection,” *Nature Reviews Immunology*, vol. 6, no. 2, pp. 127–135, 2006.

[29] A. Holländer, “Claudins provide a breath of fresh Aire,” *Nature Immunology*, vol. 8, no. 3, pp. 234–236, 2007.

[30] M. Irla, S. Hugues, J. Gill et al., “Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cellularity,” *Immunity*, vol. 29, no. 3, pp. 451–463, 2008.

[31] J. Villaseñor, W. Besse, C. Benoist, and D. Mathis, “Ectopic expression of peripheral-tissue antigens in the thymic epithelium: probabilistic, monoallelic, misinitiated,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 41, pp. 15854–15859, 2008.

[32] A. R. Hayward and M. Shreiber, “Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes,” *Journal of Immunology*, vol. 143, no. 5, pp. 1555–1559, 1989.

[33] http://www.ebi.ac.uk/miamexpress.

[34] http://www.agilent.com/chem/genespring.

[35] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, “Cluster analysis and display of genome-wide expression patterns,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 25, pp. 14863–14868, 1998.

[36] http://david.abcc.ncifcrf.gov.

[37] http://smd.stanford.edu/cgi-bin/source/sourceSearch.

[38] T. A. Fornari, P. B. Donate, C. Macedo, M. M. C. Marques, D. A. Magalhães, and G. A. S. Passos, “Age-related deregulation of Aire and peripheral tissue antigen genes in the thymic stroma of non-obese diabetic (NOD) mice is associated with autoimmune type 1 diabetes mellitus (DM-1),” *Molecular and Cellular Biochemistry*, vol. 342, no. 1-2, pp. 21–28, 2010.

[39] Q. S. Mi, D. Ly, S. E. Lamhamedi-Cherradi et al., “Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice,” *Diabetes*, vol. 52, no. 8, pp. 1967–1975, 2003.

[40] S. Kang, E.-J. Park, Y. Joe et al., “Systemic delivery of TNF-Related Apoptosis-Inducing Ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice,” *Endocrinology*, vol. 151, no. 12, pp. 5638–5646, 2010.

[41] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” *Nature Immunology*, vol. 4, no. 4, pp. 330–336, 2003.

[42] S. Horii, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” *Science*, vol. 299, no. 5609, pp. 1057–1061, 2003.

[43] J. H. Buckner, “Mechanisms of impaired regulation by CD4+ CD25+ FOXP3+ regulatory T cells in human autoimmune diseases,” *Nature Reviews Immunology*, vol. 10, no. 12, pp. 849–859, 2010.

[44] P. B. Donate, T. A. Fornari, C. M. Junta et al., “Collagen induced arthritis (CIA) in mice features regulatory transcriptional network connecting major histocompatibility complex (MHC H2) with autoantigen genes in the thymus,” *Immunobiology*, vol. 216, no. 5, pp. 591–603, 2011.